“Don’t Cure Cancer; It’s Bad For Revenue (Business)”

by ·

Ralph W. Moss, PhD, the whistleblower featured in my 3rd documentary, Second Opinion: Laetrile At Sloan-Kettering, publishes The Moss Reports blog. Ralph’s most recent post reports on how Goldman Sachs outright admitted that it would be bad for revenue if a cure for cancer was found.

“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies. While this proposition [of one-shot cures] carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”   ~ Ms. Salveen Richter, VP of Goldman’s Research Division

Read Ralph’s take on it here. Watch his video here. CNBC article here.
Looking for last minute gift ideas?

This collection includes:

  • Second Opinion: Laetrile At Sloan Kettering DVD, signed by Eric Merola
  • Doctored Results, unsigned, the companion book to the documentary, by Ralph W. Moss
  • Limited edition redux of the Second Opinion newsletter, signed by Eric Merola, 2 copies

Support the filmmaker, buy this collection now, click here. 

Tags:

You may also like...